Selecta Biosciences (SELB) Presents On New SEL-212 Phase 2 Data
SA Transcripts
140.55K Followers
The following slide deck was published by Selecta Biosciences in conjunction with this event.
117
This article was written by
140.55K Followers
Seeking Alpha's transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands of quarterly earnings calls per quarter on our site and are continuing to grow and expand our coverage. The purpose of this profile is to allow us to share with our readers new transcript-related developments. Thanks, SA Transcripts Team
Recommended For You
Comments (2)
Z
Zizu_5
11 Apr. 2018
This data looks very strong
P
PEGDr2000
12 Apr. 2018
These data look strong only up to three months (12 weeks shown in Slide 5); however, by month six (see slides 6 and 8) the patients who had not failed earlier are loosing uric acid control (three out of five patients in slide 6 and three out of three patients in slide 8). This indicates that durable tolerance to pegsiticase was not induced by any of the tested dosage regimens.Strong data would be expected to include evidence for resolution of gouty tophi, as has been reported for pegloticase (without immunosuppression).
Disagree with this article? Submit your own. To report a factual error in this article, . Your feedback matters to us!